Cargando…

SARS‐CoV‐2 vaccination and infection in ozanimod‐treated participants with relapsing multiple sclerosis

OBJECTIVE: To investigate the serologic response, predictors of response, and clinical outcomes associated with severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) vaccination and infection in ozanimod‐treated participants with relapsing multiple sclerosis (RMS) from DAYBREAK. METHODS: DAYB...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cree, Bruce A. C., Maddux, Rachel, Bar‐Or, Amit, Hartung, Hans‐Peter, Kaur, Amandeep, Brown, Elizabeth, Li, Yicong, Hu, Yanhua, Sheffield, James K., Silva, Diego, Harris, Sarah
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2023
Materias:	Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10578897/ https://www.ncbi.nlm.nih.gov/pubmed/37550942 http://dx.doi.org/10.1002/acn3.51862

Ejemplares similares

Long-term safety and efficacy of ozanimod in relapsing multiple sclerosis: Up to 5 years of follow-up in the DAYBREAK open-label extension trial
por: Cree, Bruce AC, et al.
Publicado: (2022)

Efficacy and safety of ozanimod in multiple sclerosis: Dose-blinded extension of a randomized phase II study
por: Cohen, Jeffrey A, et al.
Publicado: (2018)

Ozanimod for multiple sclerosis
Publicado: (2021)

Effect of the sphingosine-1-phosphate receptor modulator ozanimod on leukocyte subtypes in relapsing MS
por: Harris, Sarah, et al.
Publicado: (2020)

An Overview of the Efficacy and Safety of Ozanimod for the Treatment of Relapsing Multiple Sclerosis
por: Fronza, Marzia, et al.
Publicado: (2021)

Plasma neurofilament light chain concentrations as a biomarker of clinical and radiologic outcomes in relapsing multiple sclerosis: Post hoc analysis of Phase 3 ozanimod trials
por: Harris, Sarah, et al.
Publicado: (2021)

Su1480: TREATMENT-EMERGENT COVID-19 INFECTIONS IN OZANIMOD ULCERATIVE COLITIS AND MULTIPLE SCLEROSIS CLINICAL TRIALS
por: Ungaro, Ryan C., et al.
Publicado: (2022)

Ozanimod to Treat Relapsing Forms of Multiple Sclerosis: A Comprehensive Review of Disease, Drug Efficacy and Side Effects
por: Lassiter, Grace, et al.
Publicado: (2020)

Cost Per Relapse Avoided for Ozanimod Versus Other Selected Disease-Modifying Therapies for Relapsing–Remitting Multiple Sclerosis in the United States
por: Kantor, Daniel, et al.
Publicado: (2023)

Ozanimod for Treatment of Relapsing-Remitting Multiple Sclerosis in Adults: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
por: Sun, Yue, et al.
Publicado: (2020)

Comparative Efficacy and Safety of Ozanimod and Dimethyl Fumarate for Relapsing-Remitting Multiple Sclerosis Using Matching-Adjusted Indirect Comparison
por: Cohan, Stanley, et al.
Publicado: (2021)

Ozanimod: A Review in Ulcerative Colitis
por: Paik, Julia
Publicado: (2022)

"Hit smart and early" mit Ozanimod
por: Ottenjann, Henrike
Publicado: (2023)

Correction to: Ozanimod: A Review in Ulcerative Colitis
por: Paik, Julia
Publicado: (2022)

Neuroprotection by Ozanimod Following Intracerebral Hemorrhage in Mice
por: Wang, Fei, et al.
Publicado: (2022)

Effects of High‐ and Low‐Fat Meals on the Pharmacokinetics of Ozanimod, a Novel Sphingosine‐1‐Phosphate Receptor Modulator
por: Tran, Jonathan Q., et al.
Publicado: (2017)

"Hit smart and early" - MS-Therapie mit Ozanimod
por: Ottenjann, Henrike
Publicado: (2023)

Ozanimod Therapy in a Patient With Ulcerative Colitis and Multiple Sclerosis: Hitting 2 Birds With 1 Stone
por: Vuyyuru, Sudheer K., et al.
Publicado: (2023)

OzEAN Study to Collect Real-World Evidence of Persistent Use, Effectiveness, and Safety of Ozanimod Over 5 Years in Patients With Relapsing-Remitting Multiple Sclerosis in Germany
por: Ziemssen, Tjalf, et al.
Publicado: (2022)

Onset of clinical and MRI efficacy of ocrelizumab in relapsing multiple sclerosis
por: Barkhof, Frederik, et al.
Publicado: (2019)

Siponimod: Disentangling disability and relapses in secondary progressive multiple sclerosis
por: Cree, Bruce AC, et al.
Publicado: (2020)

The FLUENT study design: investigating immune cell subset and neurofilament changes in patients with relapsing multiple sclerosis treated with fingolimod
por: Cohen, Jeffrey A, et al.
Publicado: (2019)

Results From the First‐in‐Human Study With Ozanimod, a Novel, Selective Sphingosine‐1‐Phosphate Receptor Modulator
por: Tran, Jonathan Q., et al.
Publicado: (2017)

Ozanimod-Associated Iatrogenic Kaposi Sarcoma in a Patient With Ulcerative Colitis
por: Sandlow, Sarah, et al.
Publicado: (2023)

Cardiac Safety of Ozanimod, a Novel Sphingosine‐1‐Phosphate Receptor Modulator: Results of a Thorough QT/QTc Study
por: Tran, Jonathan Q., et al.
Publicado: (2017)

Concentration‐QTc Modeling of Ozanimod’s Major Active Metabolites in Adult Healthy Subjects
por: Briggs, Emily, et al.
Publicado: (2021)

Ozanimod Maintenance Therapy After Cyclosporine Induction in Acute Severe Ulcerative Colitis
por: Cohen, Nathaniel A., et al.
Publicado: (2022)

Alemtuzumab: A new therapy for active relapsing–remitting multiple sclerosis
por: Hartung, Hans-Peter, et al.
Publicado: (2015)

Network pharmacology and in silico pharmacokinetic prediction of Ozanimod in the management of ulcerative colitis: A computational study
por: Sivasakthi, Priya, et al.
Publicado: (2022)

A Literature Review of Ozanimod Therapy in Inflammatory Bowel Disease: From Concept to Practical Application
por: Becher, Noah, et al.
Publicado: (2022)

No evidence of disease activity (NEDA) analysis by epochs in patients with relapsing multiple sclerosis treated with ocrelizumab vs interferon beta-1a
por: Havrdová, Eva, et al.
Publicado: (2018)

Ocrelizumab efficacy in subgroups of patients with relapsing multiple sclerosis
por: Turner, Benjamin, et al.
Publicado: (2019)

Relapse-independent multiple sclerosis progression under natalizumab
por: Graf, Jonas, et al.
Publicado: (2021)

Su1500: COMPARATIVE EFFICACY AND SAFETY OF OZANIMOD AND USTEKINUMAB IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS
por: Dubinsky, Marla C., et al.
Publicado: (2022)

Competitive Binding of Ozanimod and Other Sphingosine 1-Phosphate Receptor Modulators at Receptor Subtypes 1 and 5
por: Selkirk, Julie V., et al.
Publicado: (2022)

Monoclonal Antibodies in the Treatment of Relapsing Multiple Sclerosis: an Overview with Emphasis on Pregnancy, Vaccination, and Risk Management
por: Krajnc, Nik, et al.
Publicado: (2022)

Multiple-Dose Pharmacokinetics of Ozanimod and its Major Active Metabolites and the Pharmacodynamic and Pharmacokinetic Interactions with Pseudoephedrine, a Sympathomimetic Agent, in Healthy Subjects
por: Tran, Jonathan Q., et al.
Publicado: (2020)

COVID-19 Outcomes and Vaccination in People with Relapsing Multiple Sclerosis Treated with Ofatumumab
por: Cross, Anne H., et al.
Publicado: (2022)

Disability improvement as a clinically relevant outcome in clinical trials of relapsing forms of multiple sclerosis
por: Cree, Bruce AC, et al.
Publicado: (2021)

Reassessment of Blood Gene Expression Markers for the Prognosis of Relapsing-Remitting Multiple Sclerosis
por: Hecker, Michael, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_t89en2r39jd3qdnhbfpgjj0369